In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022

Citation for published version:

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published in:
British Journal of Cancer

Publisher Rights Statement:
BJC open

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
In vivo pharmacology and anti-tumour evaluation of the tyrophostin tyrosine kinase inhibitor RG13022

HL McLeod1, VG Brunton1, N Eckardt1, MJ Lear2, DJ Robins2, P Workman1,* and MA Graham1†

1Cancer Research Campaign Department of Medical Oncology, University of Glasgow, Garscube Estate, Switchback Road, Bearsden, Glasgow; 2Department of Chemistry, University of Glasgow, UK.

Summary Amplification and increased expression of many growth factor receptors, including the epidermal growth factor receptor (EGFR), has been observed in human tumours. One therapeutic strategy for overcoming EGFR autocrine control of tumour growth is inhibition of EGFR protein tyrosine kinase (PTK). A series of low molecular weight molecules have been identified which inhibit the EGFR PTK in vitro and demonstrate antiproliferative activity against human cancer cell lines with high expression of EGFR. A significant growth delay in squamous cancer xenografts has been reported for one of these compounds, the tyrophostin RG13022. Based on these encouraging results, we sought to confirm the activity of RG13022 in vivo and relate the effects to the in vitro plasma disposition. RG13022 and three additional peaks were detected by HPLC following intraperitoneal administration of 20 mg kg⁻¹ RG13022 in MFI nu/nu mice. RG13022 demonstrated rapid bieponential elimination from plasma with a terminal half-life of 50.4 min. RG13022 plasma concentrations were less than 1 µM by 20 min post injection. A primary product was identified as the geometrical isomer (E)-RG13022. Both RG13022 and its geometrical isomer inhibited DNA synthesis in HN5 cells after a 24 h in vitro incubation (IC₅₀=11 µM and 38 µM respectively). Neither RG13022 nor its geometrical isomer displayed significant cytotoxicity. RG13022 had no influence on the growth of HN5 tumours when administered chronically, starting either on the day of tumour inoculation or after establishment of tumour xenografts. The rapid in vivo elimination of RG13022 has potential significance to the development of this and other related tyrophostin tyrosine kinase inhibitors, as plasma concentrations fell below that required for in vitro activity by 20 min post injection. The lack of in vivo tumour growth delay suggests that a more optimal administration schedule for RG13022 would include more frequent injections or continuous administration. An improved formulation for RG13022 is therefore required before further development of this or other similar protein tyrosine kinase inhibitors can be made. Alternative strategies should also be sought which display longer lasting in vivo exposures.

Keywords: tyrosine kinase inhibitor; tyrophostin; pharmacokinetics; tumour xenograft

The recognition that many oncogene products are involved in growth factor cell signalling pathways and that their constitutive activation in tumour cells is involved in the malignant phenotype has made proteins involved in signal transduction pathways exciting targets for the development of novel anti-cancer agents (Aaronson, 1991; Brunton and Workman, 1993). The diverse nature of these pathways leads to several possible points of pharmacological intervention, including interference with the phosphorylation of regulatory proteins via specific protein kinases. Many growth factor receptors are protein tyrosine kinases (PTKs), in which binding of ligand results in activation via phosphorylation of tyrosine residues on the receptor itself and other downstream proteins (Ullrich and Schlessinger, 1990).

Amplification of growth factor receptors has been observed for many human cancers, including epidermal growth factor, platelet-derived growth factor, fibroblast growth factor-1 and c-erbB-2 (Aaronson, 1991; Wright et al., 1989). Epidermal growth factor receptor (EGFR) has been studied most thoroughly, with high expression found in head and neck, glioma, gastraeological and breast tumours (Harris, 1990; Mendelsohn, 1990). In vitro data suggest that excessive activation of EGFR results in an altered cell phenotype, typical of malignancy (Stern et al., 1987). Furthermore, increased EGFR expression correlates with a poorer clinical outcome for patients with breast and ovarian cancer (Harris, 1994; Bartlett et al., 1996). This suggests a causal link between EGFR drive and the malignant process in man.

Several therapeutic strategies have been implemented to inactivate EGFR, including receptor antibodies, antisense oligonucleotides and PTK inhibitors. Antisense oligonucleotides for EGFR produced a reduction in cellular proliferation after prolonged incubation (Chakrabarty et al., 1995; Moroni et al., 1992). In addition, expression of antisense EGFR RNA down-modulated the expression of EGFR and decreased matrix invasion (Chakrabarty et al., 1995). Similar results have been observed after in vitro incubation with monoclonal antibodies directed against the EGFR, particularly in cell lines bearing large numbers of receptors (Mendelsohn, 1990). Significant growth delay or complete tumour regression has also been observed in human tumour xenographs after administration of EGFR monoclonal antibodies (Mendelsohn, 1990; Modjtahedi et al., 1993). The anti-tumour activity was further enhanced by co-administration of conventional cytotoxic chemotherapy (Fan et al., 1993). While antisense oligonucleotides and monoclonal antibodies against the EGFR show considerable promise as anti-tumour agents, difficulties with clinical delivery of such therapy (i.e. degradation, hypersensitivity reactions) currently restrict the application of these approaches.

Another potential mechanism for overcoming EGFR autocrine control of tumour growth is inhibition of EGFR PTK. A large series of low molecular weight molecules have been identified which inhibit the EGFR PTK in vitro and demonstrate antiproliferative activity against human cancer

Correspondence: HL McLeod, Department of Medicine and Therapeutics, University of Aberdeen, Polworth Building, Foresterhill, Aberdeen AB9 2ZD, UK
*Present address: Zeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK
†Present address: Department of Preclinical Metabolism and Pharmacokinetics, Sanofi Winthrop, Alnwick Research Centre, Willowburn Ave, Alnwick, Northumberland NE66 2JH, UK
Received 1 April 1996; revised 26 June 1996; accepted 1 July 1996
cell lines expressing high levels of EGFR (Levitzki and Gazit, 1995; Fry et al., 1994; Brunton et al., 1994; Ward et al., 1994; Traxler et al., 1995; Workman et al., 1992). Of these compounds, the tyrphostins have been the most extensively studied (Levitzki and Gazit, 1995; Levitzki, 1990). Potent tyrphostins with relative selectivity against various receptor and oncogene PTKs have been described, including those that inhibit EGFR in preference to the closely related c-erb-B2 (Levitzki and Gazit, 1995). The tyrphostin RG13022 has demonstrated inhibition of breast and squamous cell carcinoma cell growth in vitro, inhibiting 50% of colony formation after a 5–10-day incubation at 1–3 μm concentrations (Reddy et al., 1992; Yoneda et al., 1991). EGFR autophosphorylation was inhibited at similar concentrations (2–5 μm) (Reddy et al., 1992; Yoneda et al., 1991). Significant growth delay in MH-85 squamous cancer xenografts was observed after twice daily administration of RG13022 200 μg i.p. for 10 days, starting 1 day after tumour implantation (Yoneda et al., 1991). Lower doses of RG13022 failed to decrease MH-85 growth. RG13022 was reported to have no significant activity against established MH-85 tumours (Yoneda et al., 1991).

There have been very few reports on the in vivo antitumour activity of tyrosine kinase inhibitors, particularly tyrphostins. In addition, there is little information on the in vivo pharmacokinetics of such agents. The latter is particularly important since it would be envisaged that a continuous inhibition of the growth-stimulatory kinase would be required, thus necessitating chronic administration schedules that would deliver sustained plasma and tissue levels.

Based on the encouraging results reported previously (Yoneda et al., 1991), we sought to confirm the activity of RG13022 against EGFR-expressing human tumour xenografts and characterise RG13022 in vivo pharmacokinetics.

Materials and methods

Chemicals, reagents, cell lines and animals

The tyrphostin RG13022 [(Z)-2-(3’-pyridyl)-3-(3,4-dimethoxyphenoxy)propenenitrile] and its geometric isomer [(E)-2-(3’-pyridyl)-3-(3,4-dimethoxyphenoxy)propenenitrile] were synthesised in the Department of Chemistry, University of Glasgow, by an improved method (Lear et al., submitted). RG13022 was also obtained from Calbiochem (Nottingham, UK) to confirm its chromatographic profile and pharmacological activity. All chemical reagents used were analytical grade or higher (BDH, Poole, UK, or Aldrich Chemical, Milwaukee, WI, USA). The squamous cell carcinoma cell line HN5 was a kind gift from Dr Brad Ozanne (Beaston Institute, Glasow, UK) and was maintained in F10/Dulbecco’s modified Eagle medium (DMEM) with 10% fetal calf serum (Life Technologies, Paisley, UK). The HN5 cell line expressed 5.2 × 10⁶ EGFR per cell (data not shown). Athymic female nude mice (MF1 nu/nu) and non-specified mouse plasma were obtained from Harlan OLAC (Oxon, UK). They were allowed laboratory chow and water ad libitum and weighed between 20 g and 40 g.

In vivo activity

HN5 cells (5 × 10⁶ in 100 μl of phosphate-buffered saline, PBS) were injected subcutaneously into the flank of each mouse. Starting on day 0 (day of tumour inoculation), one group of ten mice received an intraperitoneal (i.p.) injection of RG13022 400 μg (15–20 mg kg⁻¹) daily for 21 days while a further control group received i.p. injections of vehicle (DMSO) only. The dose chosen was the same total daily dose administered in the study by Yoneda et al. (1991). Twice daily drug administration resulted in peritonitis, possibly from the DMSO. Tumour growth was assessed by measurement across two diameters twice weekly for 21 days after the end of treatment. The mean diameter was used to determine tumour volumes assuming spherical geometry (volume = π/6 × d³). The effect of RG13022 on established HN5 tumours was also determined. Tumour xenografts were established as described above but treatment was delayed until the tumours had reached a volume of 50 mm³. Treatments were then carried out as above for a further 21 days. Mice were weighed twice weekly during both treatment schedules.

In vivo pharmacology

The pharmacokinetic profile of RG13022 was investigated in mice after a single i.p. injection of 20 mg kg⁻¹ in 5 ml kg⁻¹ DMSO. Blood samples were taken by cardiac puncture under ether anaesthesia at 0, 2, 5, 10, 15, 20, 30, 45 and 90 min post injection. Three mice were studied per time point and plasma was pooled and frozen at −70°C for high-performance liquid chromatography (HPLC) analysis.

HPLC assay

RG13022 and its associated products were analysed in mouse plasma using reverse phase HPLC. Samples (100 μl plasma) were extracted using protein precipitation with acetonitrile, vortexed for 15 sec, and then centrifuged at 4500 r.p.m. for 2 min. Following direct injection of supernatant (75 μl), separation was achieved using a μBondapak Phenyl pre-column and C₅ Spherisorb column (4 mm × 160 mm, 5 μ). An isotropic mobile phase of 50% ammonium acetate buffer, pH 3–50% methanol (v/v) was used at 1 ml min⁻¹. Signals were detected using a photodiode array detector scanning the wavelengths from 250 to 400 nm (Waters Chromatographic Division UK, Model 991). All solvents were filtered through a 0.45 μm PTFE/propylene filter membrane (Pierce & Warriner, USA) and degassed with helium. Calibration and control samples of RG13022 were prepared in mouse plasma.

Isolation and identification of the main degradation product

Preliminary investigation of RG13022 in tissue culture media and plasma observed formation of an unidentified primary product. To determine the structure of this primary product (pp), it was isolated from plasma using a modified HPLC method and fraction collection followed by lyophilisation and identification using nuclear magnetic resonance (NMR) spectroscopy. The HPLC mobile phase was changed to water to avoid salt contamination of the substance after lyophilisation and facilitate NMR spectroscopy. The composition of the mobile phase was adjusted to 55% H₂O and 45% methanol to achieve optimum separation. Signals were detected over the range of 250 nm to 400 nm. The quality of separation was checked by analysing contour plots. The mobile phase fractions containing the pp were isolated using a Waters fraction collector (Waters Chromatographic Division, Millipore, UK). An aliquot of the collected and pooled fractions was reanalysed under the same HPLC conditions to determine peak purity. The collected fractions were then lyophilised (Freeze drier Christ ALPHA, Christ, Osterode/Harz, Germany). The isolated substance (0.2 mg) was analysed in cadmium chloride by ¹H-NMR spectroscopy (200 MHz) using a Bruker AM200SY instrument.

Antiproliferative and cytotoxic assays

The antiproliferative activity of RG13022 and its geometrical isomer against HN5 cells was determined in 96-well plates seeded at 1 × 10⁶ cells per well and maintained for 48 h. Cells were then exposed to drug at 0.1–100 μM for 24 h. [³H]-thymidine (0.1 μCi) was added to each well for the last 3 h. Cells were washed with cold PBS×3, trypsinised and harvested (Wallace 1295-001, Wallace Oy, Turku, Finland) onto a glass fibre filtermat (Wallace Oy). Incorporation of [³H]-thymidine into DNA was then determined by automated scintillation counter (Wallace 1205 BETAPLATE, Wallace Oy) and used as a measure of growth inhibition. The
cytotoxic activity of RG13022 and its geometrical isomer against HN5 cells was determined in 96-well plates seeded at 1 x 10^4 cells per well and maintained for 48 h. Cells were then exposed to drug at 0.1–100 µM for 24 h. Cells were then maintained in drug-free medium for 72 h, with media replaced daily. Reduction of tetrazolium dye was determined after addition of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium (MTT) to each well for 4 h, solubilised in DMSO and glycine buffer, and measured at 570 nm (Plumb et al., 1989). Using this protocol, the MTT assay is a measure of cytotoxicity, as cells are allowed to recover through 2–3 cell cycles post treatment in this protocol (Plumb et al., 1989).

Results

A sensitive and precise automated HPLC assay for detection of RG13022 and related products in mouse plasma was developed. RG13022 in DMSO had a maximum absorbance (λ max) at 353 nm and retention time of 21 min. The calibration curve was linear over the range 0.1 µg ml⁻¹ to 20 µg ml⁻¹ (r²=0.9986). The lower limit of detection was 50 ng ml⁻¹. The assay precision, determined at 1 µg ml⁻¹, had a coefficient of variation of 6.0% (n = 10).

The plasma disposition of RG13022 and its pp were characterised in MF1 nu/nu mice. Four drug related peaks could be detected by HPLC. The drug-related peaks appeared at 7.4, 9.1, 13.4 and 21.3 min retention time (Figure 1). The peak with a retention time of 21.3 min coeluted with RG13022 and had the same spectrum. Three additional peaks were also detected in mouse plasma following intraperitoneal administration of 20 mg kg⁻¹ RG13022. The peak at 9.1 min was consistent with the pp. The peaks at 7.4 and 13.4 min were only observed in vivo and were thought to be metabolites. The maximum concentration of RG13022 in plasma, measured at the 2 min time point, was 6.3 µg ml⁻¹ (28 µM). RG13022 demonstrated rapid biexponential elimination from plasma with a clearance of 195 ml min⁻¹ kg⁻¹ and terminal half-life (t½) of 50.4 min (Figure 2). Based on the peak areas of chromatograms taken at 340 nm wavelength, the pp had a faster rate of elimination (terminal t½ of 23.8 min). RG13022 plasma concentrations were less than 1 µM by 20 min post injection.

It was possible to separate and isolate the pp from tissue culture media and plasma. After lyophilisation a yellow substance was isolated and analysed by ¹H-NMR spectroscopy. The geometrical (E) isomer was prepared by irradiation of RG13022 and reference spectra were obtained (Lear et al., submitted). The pp was identified by comparison of its spectral data with those of the (E) isomer, which were identical. The most striking features of the NMR spectrum of the (E) isomer were the methoxy methyl signals at different chemical shifts of 3.48 and 3.82. In the spectrum of the (Z) isomer (RG13022) these signals are much closer in chemical shift at 3.89 and 3.91.

Inhibition of DNA synthesis was observed in the HN5 cells after 24 h exposure to RG13022 (IC₅₀ = 11.0 ± 0.8 µM; Figure 3a). The (E) isomer was a less potent inhibitor of H-timidine incorporation (IC₅₀ = 38.0 ± 1.8 µM Figure 3a).

Neither RG13022 nor the geometrical isomer displayed significant cytotoxicity, with a <10% decrease in viable cells after 24 h incubation with 100 µM (Figure 3b). Chromatographic analysis of RG13022 in tissue culture media demonstrated >90% stability over 24 h at 37°C. The pp was present in tissue culture media by 3 h and reached 6% of the total tyrosphostin concentration.

RG13022 had no influence on the growth of HN5 squamous tumours when administered once daily for 21 days starting on the day of tumour inoculation or after the tumour xenografts had grown to a volume of 50 mm³ (Figure 4). No difference in body weight was observed for any treatment group.

Discussion

Inhibition of PTK offers a novel approach to anti-cancer drug therapy. Altering the cellular signalling response to receptor activation would provide a mechanism for slowing tumour growth and complement conventional, DNA-directed chemotherapy (Workman et al., 1992). In particular, the tyrosphostin class of PTK inhibitors have shown great promise in vitro antiproliferative and receptor phosphorylation studies (Levitzki and Gazit, 1995; Levitzki, 1990). The reversible nature of receptor tyrosine kinase inhibition may necessitate frequent drug administration schedules to achieve a continuous inhibition of the growth-factor stimulated proliferation. Therefore, in vivo characterisation of tyrosphostin disposition is required to design schedules that would deliver sustained plasma and tissue levels. This report is the first to characterise the in vivo disposition of a tyrosphostin PTK inhibitor.

RG13022 was rapidly absorbed after injection and was detectable at the earliest measured time point (2 min). The
rapid absorption could be due to the hydrophobic nature and low molecular weight of the compound and may be influenced
by the vehicle (DMSO). The peak plasma level was
6.34 µg ml\(^{-1}\) or 28 µM. This concentration is 2.5-fold higher
than the IC\(_{50}\) of RG13022-associated inhibition of HN5 DNA
synthesis after a 24 h incubation. The concentrations needed
for in vivo activity of tyrphostins are not known. It has been
reported that IC\(_{50}\) values for the antiproliferative activity of
tyrophostins in whole organ culture are 5–10 times higher than
in cell culture (Dvir et al., 1991). Nevertheless, our results,
together with the report of RG13022 in vivo activity, indicate
that pharmacologically relevant concentrations are achievable
in vivo (Yoneda et al., 1991). The terminal half-life of RG13022,
determined from plasma samples measured over 90 min, was
estimated to be 50.4 min. Although optimum assessment of
terminal elimination is made after drug measurement over a 4–
5 half-life time interval, RG13022 was not detectable in plasma
by 2 h post injection. Therefore, it is unlikely that sufficient
quantity of drug was present for continuous inhibition of
receptor tyrosine kinase activity. However, caution should be
applied with the extrapolation of plasma tyrphostin exposure
as a surrogate marker of tumour exposure. The pharmacoki-
etic profile of tumour RG13022 is not known as tissue levels
were not evaluated.

Together with RG13022, three other drug-related sub-
stances were observed, with the largest peak eluting at 9 min.
No standards were available, and therefore these substances
could not be quantified. One of these drug-related substances
showed the chromatographic and spectral characteristics of
the pp. Extensive NMR spectroscopy and chromatographic
analysis identified the pp as the (E) isomer of RG13022. The
product was rapidly formed in vivo and had a terminal \(t_{1/2}\) of
23.9 min. It is not possible to deduce from these data if the
formation of this substance in vivo occurred before the
absorption of the parent drug from the peritoneum or within
the plasma. The pp was not detectable in the drug solution
used for in vivo studies. The plasma profiles of the two other
drug-related peaks reflected the production of metabolites.
An initial increase in plasma concentration of these
metabolites was followed by a biexponential decline.
Formation of these substances before absorption, followed
by a slower absorption profile than RG13022, is also possible.
However, substances with similar chromatographic and spectral characteristics were not seen in vitro experiments
(unpublished observations).

Yoneda et al. (1991) mentioned that RG13022 undergoes
light-induced isomerisation, but assumed that the two
isomeric forms were equally active. This contrasts with the

![Figure 3](image1.png)

**Figure 3** Inhibition of (a) \(^{[3]}\)Hthymidine incorporation and (b) cytotoxicity of RG13022 (○) and its (E) isomer (●) in HN5 cells
after 24 h incubation.

![Figure 4](image2.png)

**Figure 4** The influence of RG13022 on in vivo growth of HN5 xenografts following 400 µg daily for 21 days after (a) the
implantation of tumour or (b) tumours had reached a volume of
50 mm\(^3\). ■, RG13022; ○, vehicle.
results of the current work, in which the (E) isomer was found to be one third as potent as the (Z) isomer (RG13022) inhibiting HN5 DNA synthesis after 24 h in vitro incubation. Therefore, evaluation of RG13022 disposition alone will give an underestimate of the agent’s systemic exposure.

In contrast to the findings of Yoneda et al. (1991), RG13022 demonstrated no anti-tumour activity against human tumour xenografts in the current study. The absence of tumour growth suppression was found when RG13022 was administered chronically for 21 days from the day of tumour inoculation or after tumour establishment had occurred. Although both studies used squamous cell carcinoma cell lines with high levels of EGFR, differences in cell signalling, downstream targets or death pathways between the cell lines may contribute greatly to the in vivo activity of RG13022 previously described (Modjtahedi et al., 1993; Yoneda et al., 1991). However, previous studies have demonstrated in vivo inhibition of HN5 tumour growth by EGFR antibodies (Modjtahedi et al., 1993). This demonstrates that HN5 cells are susceptible to growth inhibition by targeting the EGFR. An additional difference between the study of Yoneda et al. (1991) and the current study was the drug administration schedule. Yoneda et al. (1991) administrated drug at 200 μg mouse twice daily (400 μg total dose), whereas in the current study we administered the same dose as a single daily injection. The rapid elimination of RG13022 resulted in plasma concentrations <1 μM by 20 min after injection. The rate of drug degradation of other tyrosphostin compounds has also been shown to influence the degree of in vitro PTK inhibitory activity against pp60^src and EGFR (Ramdas et al., 1994). The antiproliferative activity of RG13022 has an IC50 of 2 – 20 μM against human cancer cell lines after prolonged (> 16 h) in vitro incubations (data not shown) (Reddy et al., 1992; Yoneda et al., 1991). In addition, although RG13022 had potent inhibitory activity against HN5 cell line DNA synthesis, little cytotoxic activity was observed for either RG13022 or its geometric isomer. This suggests that a better administration schedule for RG13022 would include frequent injections or continuous administration. In the current study twice daily administration of RG13022 was not tolerated by the MF1 nu/nu mice because of the toxicity of the DMSO drug vehicle (data not shown). An improved formulation for RG13022 is therefore required before the in vivo activity of this PTK inhibitor can be assessed further. The results also highlight the need to develop more water-soluble tyrosine kinase inhibitors that give sustained plasma and tissue exposures, as continuous blockage of the tyrosine kinase signal is likely to be required for growth inhibition.

Acknowledgements
This work was supported by the Cancer Research Campaign (UK). Dr McLeod was the recipient of a NCI-EORTC Exchange Award. Dr Lear was the recipient of a Glasgow University (Senate) Scholarship. Professor Workman acknowledges the award of a Cancer Research Campaign Life Fellowship.

References

